oHCM drug Camzyos's last hurdle to reimb remains high
By Eo, Yun-Ho | translator Alice Kang
24.10.15 05:11:45
°¡³ª´Ù¶ó
0
NHIS decides to extend drug price negotiations for the oHCM drug
Government and pharmaceutical company disagree over patient numbers, etc.
According to industry sources, the drug pricing negotiations between BMS Pharmaceuticals Korea and the National Health Insurance Service (NHIS) for the obstructive hypertrophic cardiomyopathy (oHCM) drug Camzyos (mavacamten) have been extended after failing to finalize the deal within the deadline.
The deadline extension was primarily due to a disagreement over the number of patients eligible for Camzyos.
Camzyos¡¯ reimbursement journey faced difficulties, receiving a redeliberation decision from the Health Insurance Review and Assessment
Eo, Yun-Ho(unkindfish@dailypharm.com)
If you want to see the full article, please JOIN US (click)